Expression of Ki-67 as a proliferation marker in prostate cancer

Sulik, M; Maruszak, Klaudia; Puchalska, Joanna; Misiukiewicz-Poć, Magdalena

doi:10.1016/s1230-8013(11)70019-4

Cited by 13 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[32]They confirmed the association between survival and Ki67 index.This implies that high grade tumors have increased proliferative potential by virtue of which they show high proliferating index and hence poor prognosis.In relation to sPSA levels and Ki67, limited data from different studies conclude that there is no statistically significant correlation between serum PSA levels and Ki67 labeling index. [32][33][34][35]Only one study by Luczynska E et al had similar findings as our study. [35]High grade tumors or tumors with poor differentiation are known to be associated with decreased serum PSA levels.These become outliers and predominance of such cases in a study may affect the correlation between these two variables.We had a sample size of 100 and there were 39 cases of high grade tumor with less outliers .Due to large sample size and more number of high grade tumors the effect of these have got nullified and hence we got the above results.…”

Section: Discussionsupporting

confidence: 90%

“…[32][33][34][35]Only one study by Luczynska E et al had similar findings as our study. [35]High grade tumors or tumors with poor differentiation are known to be associated with decreased serum PSA levels.These become outliers and predominance of such cases in a study may affect the correlation between these two variables.We had a sample size of 100 and there were 39 cases of high grade tumor with less outliers .Due to large sample size and more number of high grade tumors the effect of these have got nullified and hence we got the above results.…”

Section: Discussionsupporting

confidence: 90%

“…[20]The various studies on Ki67 expression use different grouping of Gleason scores. [26][27][28][29][30][31][32][33][34][35]The studies mentioned in the table used same system as followed in present study and the comparative data is presented in table 6.Our study patient cohort is similar to study by Fisher G with more number of moderately differentiated tumors. [27]Various studies(table 6) report different ranges of Ki67 expression in CaPs in their literature.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Histopathological Study of Prostatic Carcinoma in Relation to Gleason Grade, Serum PSA and Ki67 Immunomarker

Mahadev

Vani

Murthy

2018

APALM

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histopathological Study of Prostatic Carcinoma in Relation to Gleason Grade, Serum PSA and Ki67 Immunomarker

Mahadev

Vani

Murthy

2018

APALM

View full text Add to dashboard Cite

show abstract

“…Ki-67 is a protein expressed in the nucleus of proliferating cells during mitosis interphase. It is expressed during late G1, S, G2, and M phases, but not during G0 phase ( 15 ). The Ki-67 protein is a cellular proliferation marker ( 16 , 17 ) and it is widely used given its high reproducibility ( 15 ).…”

Section: Resultsmentioning

confidence: 99%

“…Among the most frequent biomarkers studied that are associated with PCa are p53 (tumor protein p53), Ki-67 (marker of proliferation), ERG (ETS-related gene), MYC (proto-oncogene), and PTEN (phosphatase and tensin homolog), which are implicated in the control of cell proliferation and differentiation, angiogenesis, and apoptosis ( 15 – 25 ).…”

Section: Introductionmentioning

confidence: 99%

The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature

et al. 2018

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is a heterogeneous disease that lends itself toward numerous therapeutic options depending on its risk stratification. One of the greatest challenges in PCa urologic practice is to select patients who should be referred for biopsy and, for those patients who are diagnosed with cancer, to differentiate between patients with indolent disease from those with an unfavorable prognosis and, to determine ideal patient management and avoid unnecessary interventions. Accordingly, there is a growing body of literature reporting immunohistochemical studies with the objective of determining a prostate cancer prognosis. Among the most frequent biomarkers studied are Ki-67, p53, PTEN, MYC, and ERG. Based on these findings, we systematically reviewed articles that assessed the role of these main prognostic markers in prostate cancer.Methods: Consistent with PRISMA guidelines, we performed a systematic literature search throughout the Web of Science and PubMed Medline databases. We considered all types of studies evaluating the role of Ki-67, p53, PTEN, MYC, and ERG immunohistochemical analysis in prostate cancer until July 2017.Results: We identified 361 articles, 44 of which were summarized in this review. Diagnostically, no single immunohistochemical marker was able to define a tumor as benign or malignant. Prognostically, Ki-67, p53, and MYC were related to the tumor grade given by Gleason score and to the tumor stage (higher levels related to higher tumor grade). Furthermore, Ki-67 was also related to higher PSA levels, shorter disease-free intervals and shorter tumor-specific survival; the latter was also related to p53. The loss of PTEN protein expression showed a higher association with biochemical recurrence and with a worse prognosis, beyond that predicted by the Gleason score and tumor stage. ERG staining also showed a strong association with biochemical recurrence.Conclusion: There are several studies relating immunohistochemical markers with clinical-laboratorial outcomes in prostate cancer, the most frequent being Ki-67, p53, ERG, PTEN, and MYC. However, none of these markers have been validated by literary consensus to be routinely applied in medical practice.

show abstract

Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues

et al. 2016

View full text Add to dashboard Cite

Protein kinase CK2 plays a critical role in cell growth, proliferation, and suppression of cell death. CK2 is overexpressed, especially in the nuclear compartment, in the majority of cancers, including prostate cancer (PCa). CK2-mediated activation of transcription factor nuclear factor kappa B (NF-κB) p65 is a key step in cellular proliferation, resulting in translocation of NF-κB p65 from the cytoplasm to the nucleus. As CK2 expression and activity are also elevated in benign prostatic hyperplasia (BPH), we sought to increase the knowledge of CK2 function in benign and malignant prostate by examination of the relationships between nuclear CK2 and nuclear NF-κB p65 protein expression. The expression level and localization of CK2α and NF-κB p65 proteins in PCa and BPH tissue specimens was determined. Nuclear CK2α and NF-κB p65 protein levels are significantly higher in PCa compared with BPH, and these proteins are positively correlated with each other in both diseases. Nuclear NF-κB p65 levels correlated with Ki-67 or with cytoplasmic NF-κB p65 expression in BPH, but not in PCa. The findings provide information that combined analysis of CK2α and NF-κB p65 expression in prostate specimens relates to the disease status. Increased nuclear NF-κB p65 expression levels in PCa specifically related to nuclear CK2α levels, indicating a possible CK2-dependent relationship in malignancy. In contrast, nuclear NF-κB p65 protein levels related to both Ki-67 and cytoplasmic NF-κB p65 levels exclusively in BPH, suggesting a potential separate impact for NF-κB p65 function in proliferation for benign disease as opposed to malignant disease.

show abstract

Expression of Ki-67 as a proliferation marker in prostate cancer

Cited by 13 publications

References 15 publications

Histopathological Study of Prostatic Carcinoma in Relation to Gleason Grade, Serum PSA and Ki67 Immunomarker

Histopathological Study of Prostatic Carcinoma in Relation to Gleason Grade, Serum PSA and Ki67 Immunomarker

The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature

Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues

Contact Info

Product

Resources

About